Precision BioSciences

Precision BioSciences Secures U.S. Patent Allowances for PBGENE-HBV Program

Precision BioSciences Receives U.S. Patent Allowances Covering the PBGENE-HBV Program Precision BioSciences, Inc. a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it has received…

Read MorePrecision BioSciences Secures U.S. Patent Allowances for PBGENE-HBV Program
Parabilis

Parabilis Medicines’ Zolucatetide Receives FDA Orphan Drug Designation for Desmoid Tumor Treatment

Parabilis Medicines’ Zolucatetide, the First and Only Direct Inhibitor of the Elusive β-catenin:TCF Interaction, Receives FDA Orphan Drug Designation for the Treatment of Desmoid Tumors Parabilis Medicines, a clinical-stage biopharmaceutical company committed to creating extraordinary medicines for people living with…

Read MoreParabilis Medicines’ Zolucatetide Receives FDA Orphan Drug Designation for Desmoid Tumor Treatment
Eurofins Biomnis

Eurofins Biomnis Launches Advanced LC-MS/MS Test for Cereulide Toxin Detection in Stool

Eurofins Biomnis Launches New Clinical LC‑MS/MS Method for the Detection of Cereulide Toxin in Stool Samples Eurofins Biomnis, a leading European provider of specialised clinical diagnostics services, and part of the global network of Eurofins laboratories, announces the successful development…

Read MoreEurofins Biomnis Launches Advanced LC-MS/MS Test for Cereulide Toxin Detection in Stool
Curatis

Curatis Grants Neupharma Exclusive Japan Rights for Corticorelin (C-PTBE-01)

Curatis and Neupharma Announce Exclusive Licensing Agreement to Develop and Market Corticorelin (C-PTBE-01) for the Treatment of Peritumoral Brain Edema in Japan Curatis Holding AG and Neupharma Co., Ltd. a Japanese pharmaceutical company specializing in oncology, immunology, pulmonology and cardiology…

Read MoreCuratis Grants Neupharma Exclusive Japan Rights for Corticorelin (C-PTBE-01)
IFF

IFF Expands Latin America Footprint with New Enzyme Hub and Applications Lab in Brazil

IFF Expands Production and Innovation Capabilities in Latin America with New Enzyme Hub and Applications Laboratory Global ingredients and biosciences leader IFF is strengthening its footprint in Latin America through a strategic expansion designed to boost production capacity, innovation, and…

Read MoreIFF Expands Latin America Footprint with New Enzyme Hub and Applications Lab in Brazil
TIXiMED-

TIXiMED: Oral TIX100 Prevents Post-GLP-1 Weight Regain in Preclinical Study

TIXiMED Reports Promising Preclinical Results for Oral TIX100 in Preventing Weight Regain After GLP-1 Therapy TIXiMED a clinical-stage pharmaceutical company focused on developing innovative treatments for diabetes and metabolic diseases, has announced encouraging new preclinical findings for its investigational oral…

Read MoreTIXiMED: Oral TIX100 Prevents Post-GLP-1 Weight Regain in Preclinical Study
Biosciences

First Patient Dosed in Emalex Biosciences’ Expanded Access Program for Investigational Tourette Syndrome Therapy

First Patient Dosed in Emalex Biosciences’ Expanded Access Program for Investigational Tourette Syndrome Therapy Emalex Biosciences today announced that the first patient was dosed in its Expanded Access Program for ecopipam, an investigational first-in-class D1 receptor antagonist in development for…

Read MoreFirst Patient Dosed in Emalex Biosciences’ Expanded Access Program for Investigational Tourette Syndrome Therapy